Cargando…

Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use

BACKGROUND AND AIMS: It is currently unclear whether sodium–glucose co-transporter 2 (SGLT2) inhibitor administration can improve the insulin sensitivity as well as rapidly reduce plasma glucose concentrations in humans during the early phase of treatment initiation. This study aimed to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Goto, Yuka, Otsuka, Yoshie, Ashida, Kenji, Nagayama, Ayako, Hasuzawa, Nao, Iwata, Shimpei, Hara, Kento, Tsuruta, Munehisa, Wada, Nobuhiko, Motomura, Seiichi, Tajiri, Yuji, Nomura, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354734/
https://www.ncbi.nlm.nih.gov/pubmed/32580152
http://dx.doi.org/10.1530/EC-20-0082
_version_ 1783558152122269696
author Goto, Yuka
Otsuka, Yoshie
Ashida, Kenji
Nagayama, Ayako
Hasuzawa, Nao
Iwata, Shimpei
Hara, Kento
Tsuruta, Munehisa
Wada, Nobuhiko
Motomura, Seiichi
Tajiri, Yuji
Nomura, Masatoshi
author_facet Goto, Yuka
Otsuka, Yoshie
Ashida, Kenji
Nagayama, Ayako
Hasuzawa, Nao
Iwata, Shimpei
Hara, Kento
Tsuruta, Munehisa
Wada, Nobuhiko
Motomura, Seiichi
Tajiri, Yuji
Nomura, Masatoshi
author_sort Goto, Yuka
collection PubMed
description BACKGROUND AND AIMS: It is currently unclear whether sodium–glucose co-transporter 2 (SGLT2) inhibitor administration can improve the insulin sensitivity as well as rapidly reduce plasma glucose concentrations in humans during the early phase of treatment initiation. This study aimed to investigate the effect of SGLT2 inhibitor on insulin sensitivity in the early phase of treatment initiation. METHODS AND RESULTS: This single-center, open label, and single-arm prospective study recruited 20 patients (14 men) with type 2 diabetes mellitus (T2DM). We examined the patients’ metabolic parameters before and 1 week after SGLT2 inhibitor (10 mg/day of empagliflozin) administration. The glucose infusion rate (GIR) was evaluated using the euglycemic hyperinsulinemic glucose clamp technique. Changes in laboratory and anthropometric parameters before and after SGLT2 inhibitor administration were analyzed according to the change in the GIR. The BMI, body fat amount, skeletal muscle amount, systolic blood pressure, and triglyceride level significantly decreased along with the treatment, while urinary glucose level and log GIR value significantly increased. Notably, changes in the GIR after SGLT2 inhibitor administration, which indicated improvement in peripheral insulin sensitivity, were negatively correlated with T2DM duration and positively with reduction in fluctuation of daily plasma glucose profiles before and after treatment. CONCLUSION: SGLT2 inhibitor improved insulin sensitivity in the skeletal muscle independent of anthropometric changes. Patients with short duration of T2DM and insulin resistance can be good candidates for short-term SGLT2 inhibitor administration to improve insulin sensitivity in the skeletal muscle.
format Online
Article
Text
id pubmed-7354734
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-73547342020-07-15 Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use Goto, Yuka Otsuka, Yoshie Ashida, Kenji Nagayama, Ayako Hasuzawa, Nao Iwata, Shimpei Hara, Kento Tsuruta, Munehisa Wada, Nobuhiko Motomura, Seiichi Tajiri, Yuji Nomura, Masatoshi Endocr Connect Research BACKGROUND AND AIMS: It is currently unclear whether sodium–glucose co-transporter 2 (SGLT2) inhibitor administration can improve the insulin sensitivity as well as rapidly reduce plasma glucose concentrations in humans during the early phase of treatment initiation. This study aimed to investigate the effect of SGLT2 inhibitor on insulin sensitivity in the early phase of treatment initiation. METHODS AND RESULTS: This single-center, open label, and single-arm prospective study recruited 20 patients (14 men) with type 2 diabetes mellitus (T2DM). We examined the patients’ metabolic parameters before and 1 week after SGLT2 inhibitor (10 mg/day of empagliflozin) administration. The glucose infusion rate (GIR) was evaluated using the euglycemic hyperinsulinemic glucose clamp technique. Changes in laboratory and anthropometric parameters before and after SGLT2 inhibitor administration were analyzed according to the change in the GIR. The BMI, body fat amount, skeletal muscle amount, systolic blood pressure, and triglyceride level significantly decreased along with the treatment, while urinary glucose level and log GIR value significantly increased. Notably, changes in the GIR after SGLT2 inhibitor administration, which indicated improvement in peripheral insulin sensitivity, were negatively correlated with T2DM duration and positively with reduction in fluctuation of daily plasma glucose profiles before and after treatment. CONCLUSION: SGLT2 inhibitor improved insulin sensitivity in the skeletal muscle independent of anthropometric changes. Patients with short duration of T2DM and insulin resistance can be good candidates for short-term SGLT2 inhibitor administration to improve insulin sensitivity in the skeletal muscle. Bioscientifica Ltd 2020-06-04 /pmc/articles/PMC7354734/ /pubmed/32580152 http://dx.doi.org/10.1530/EC-20-0082 Text en © 2020 The authors http://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Research
Goto, Yuka
Otsuka, Yoshie
Ashida, Kenji
Nagayama, Ayako
Hasuzawa, Nao
Iwata, Shimpei
Hara, Kento
Tsuruta, Munehisa
Wada, Nobuhiko
Motomura, Seiichi
Tajiri, Yuji
Nomura, Masatoshi
Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use
title Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use
title_full Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use
title_fullStr Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use
title_full_unstemmed Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use
title_short Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use
title_sort improvement of skeletal muscle insulin sensitivity by 1 week of sglt2 inhibitor use
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354734/
https://www.ncbi.nlm.nih.gov/pubmed/32580152
http://dx.doi.org/10.1530/EC-20-0082
work_keys_str_mv AT gotoyuka improvementofskeletalmuscleinsulinsensitivityby1weekofsglt2inhibitoruse
AT otsukayoshie improvementofskeletalmuscleinsulinsensitivityby1weekofsglt2inhibitoruse
AT ashidakenji improvementofskeletalmuscleinsulinsensitivityby1weekofsglt2inhibitoruse
AT nagayamaayako improvementofskeletalmuscleinsulinsensitivityby1weekofsglt2inhibitoruse
AT hasuzawanao improvementofskeletalmuscleinsulinsensitivityby1weekofsglt2inhibitoruse
AT iwatashimpei improvementofskeletalmuscleinsulinsensitivityby1weekofsglt2inhibitoruse
AT harakento improvementofskeletalmuscleinsulinsensitivityby1weekofsglt2inhibitoruse
AT tsurutamunehisa improvementofskeletalmuscleinsulinsensitivityby1weekofsglt2inhibitoruse
AT wadanobuhiko improvementofskeletalmuscleinsulinsensitivityby1weekofsglt2inhibitoruse
AT motomuraseiichi improvementofskeletalmuscleinsulinsensitivityby1weekofsglt2inhibitoruse
AT tajiriyuji improvementofskeletalmuscleinsulinsensitivityby1weekofsglt2inhibitoruse
AT nomuramasatoshi improvementofskeletalmuscleinsulinsensitivityby1weekofsglt2inhibitoruse